C4 Therapeutics, Inc.CCCCNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P22
Within normal range
vs 3Y Ago
-1.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -3.87% |
| Q3 2025 | -0.79% |
| Q2 2025 | -3.23% |
| Q1 2025 | -16.73% |
| Q4 2024 | 2.12% |
| Q3 2024 | 34.04% |
| Q2 2024 | 5.41% |
| Q1 2024 | -25.86% |
| Q4 2023 | 7.21% |
| Q3 2023 | -5.28% |
| Q2 2023 | 3.04% |
| Q1 2023 | -5.25% |
| Q4 2022 | 3.33% |
| Q3 2022 | -5.30% |
| Q2 2022 | 19.54% |
| Q1 2022 | -1.31% |
| Q4 2021 | 9.25% |
| Q3 2021 | 4.36% |
| Q2 2021 | 13.45% |
| Q1 2021 | 0.46% |
| Q4 2020 | -14.63% |
| Q3 2020 | 34.77% |
| Q2 2020 | 8.88% |
| Q1 2020 | 1.84% |
| Q4 2019 | 27.86% |
| Q3 2019 | 0.00% |
| Q2 2019 | 31.22% |
| Q1 2019 | 0.00% |